Short interfering RNAs (siRNA) are a powerful class of genetic medicines whose clinical
translation can be hindered by their suboptimal delivery properties in vivo. Here, we provide …

Introduction Hypertension is the main global risk factor for cardiovascular disease. Despite
this, less than half of treated hypertensive patients are controlled. One reason for this is …

The prevalence of arterial hypertension is approximately 47% in the United States and 55%
in Europe. Multiple different medical therapies are used to treat hypertension including …

近年来, 生物技术药研发涌现于心血管病治疗, 包括多肽, 单克隆抗体, 反义寡核苷酸,
小干扰核糖核酸, 基因编辑疗法和治疗性疫苗. 这些信息令人鼓舞, 部分药物已经批准临床应用 …

Correspondence to: Xiao Wang, PhD, Perelman School of Medicine at the University of
Pennsylvania, 3400 Civic Center Blvd, Bldg 421, 11-104 Smilow Center for Translational …

Hypertension is a common noncommunicable condition estimated to affect over one billion
adults worldwide, with a prevalence that has doubled over the past 20 years [1]. From 2012 …

针对高血压这一主要心血管病危险因素进行有效防治, 可以降低心血管病死亡风险. 然而,
中国高血压的知晓率, 治疗率和控制率均处于较低水平, 尤其是控制率极低 …

RNA-based therapies are currently used for immunisation against infections and to treat
metabolic diseases. They can modulate gene expression in immune cells and hepatocytes …

Hypertension is a prevalent public health problem, contributing to> 10 million deaths
annually. Though multiple therapeutics exist, many patients suffer from treatment-resistant …

Hypertension is the leading risk factor for cardiovascular diseases; however, only one-fifth of
the treated population is believed to attain sufficient blood pressure control level s. A …